AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-74. (Canceled)

75. (Currently amended) A method of inhibiting Raf kinase activity in a human or animal subject suffering from a Ras/mitogen-activated protein kinase signal pathway-mediated cancer disorder selected from the group consisting of melanoma, breast cancer, prostate cancer, lung cancer, pancreatic cancer, thyroid cancer, bladder cancer, colon cancer, liver cancer, myeloid leukemia, and villous colon adenoma, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (II) effective to inhibit Raf kinase activity in the human or animal subject:



(II)

wherein Y is O;

A_1 is substituted ~~or unsubstituted alkyl, cycloalkyl, heterocycloalkyl,~~ aryl, ~~polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl~~;

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

A_2 is ~~substituted or~~ unsubstituted heteroaryl;

~~R_1 is O or H, and R_2 is NR_5R_6 or hydroxyl; or~~ R_1 is taken together with R_2 to form a substituted ~~or unsubstituted heterocycloalkyl or~~ heteroaryl group; wherein, the dashed line represents a single or double bond;

R_3 is hydrogen~~, halogen, loweralkyl, or loweralkoxy~~; and

R_4 is ~~hydrogen, hydroxyl, alkylamino, dialkylamino or~~ alkyl; [[and]]

~~R_5 and R_6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R_5 and R_6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl;~~

or a pharmaceutically acceptable salt thereof.

76. (Previously presented) The method of claim 75 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

77. (Canceled)

78. (Currently amended) A method of inhibiting Raf kinase activity in a human or animal subject suffering from a Ras/mitogen-activated protein kinase signal pathway-mediated hormone dependent cancer disorder selected from the group consisting of breast cancer and prostate cancer, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (II) effective to inhibit Raf kinase activity in the human or animal subject:

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



(II)

wherein Y is O;

A_1 is substituted ~~or unsubstituted alkyl, cycloalkyl, heterocycloalkyl,~~ aryl, ~~polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl~~;

A_2 is ~~substituted or~~ unsubstituted heteroaryl;

~~R_1 is O or H, and R_2 is NR_5R_6 or hydroxyl; or~~ R_1 is taken together with R_2 to form a substituted ~~or unsubstituted heterocycloalkyl or~~ heteroaryl group; wherein, the dashed line represents a single or double bond;

R_3 is hydrogen~~, halogen, loweralkyl, or loweralkoxy~~; and

R_4 is ~~hydrogen, hydroxyl, alkylamino, dialkylamino or~~ alkyl; [[and]]

~~R_5 and R_6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R_5 and R_6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl;~~

or a pharmaceutically acceptable salt thereof.

79. (Canceled)

80. (Previously presented) The method of claim 78 which further comprises administering to the human or animal subject at least one additional agent for the treatment of

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

81. (Canceled)

82. (Currently amended) A method of inhibiting Raf kinase activity in a human or animal subject suffering from a Ras/mitogen-activated protein kinase signal pathway-mediated hematological cancer disorder, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (II) effective to inhibit Raf kinase activity in the human or animal subject:



(II)

wherein Y is O;

A_1 is substituted ~~or unsubstituted alkyl, cycloalkyl, heterocycloalkyl,~~ aryl, ~~polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl~~;

A_2 is ~~substituted or~~ unsubstituted heteroaryl;

~~R_1 is O or H, and R_2 is NR_5R_6 or hydroxyl; or~~ R_1 is taken together with R_2 to form a substituted ~~or unsubstituted heterocycloalkyl or~~ heteroaryl group; wherein, the dashed line represents a single or double bond;

R_3 is hydrogen~~, halogen, loweralkyl, or loweralkoxy~~; and

R_4 is ~~hydrogen, hydroxyl, alkylamino, dialkylamino or~~ alkyl; [[and]]

~~R_5 and R_6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R_5 and R_6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl;~~

or a pharmaceutically acceptable salt thereof.

83. (Previously presented) The method of claim 82 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

84-87. (Canceled)

88. (Currently amended) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein R_4 in formula (II) is ~~hydrogen or~~ C_{1-6} alkyl.

89. (Previously presented) The method of claim 88, wherein R_4 in formula (II) is methyl.

90. (Canceled)

91. (Currently amended) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein A_1 in formula (II) is a substituted ~~or unsubstituted C_{3-14} aryl~~ carbocyclic aryl group.

92. (Currently amended) The method of claim [[91]] 75, wherein A_1 in formula (II) is selected from the group consisting of substituted ~~or unsubstituted~~ phenyl, pyridyl, pyrimidinyl,

~~phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclylcarbonylphenyl, heterocyclylphenyl, heterocyclylalkylphenyl, chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene,~~ thiophenyl, ~~thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl,~~ indenyl, ~~2,3-dihydroindenyl, tetralinyl, trifluorophenyl, (trifluoromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N-morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl,~~ indolyl, ~~2,3-dihydroindolyl, 1-acetyl-2,3-dihydroindolyl, cycloheptyl, bicyclo[2.2.1]hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-1-ylalkyl, 4-amino(imino)methylphenyl,~~ isoxazolyl, indazolyl, ~~adamantyl, bicyclohexyl, quinuclidinyl,~~ imidazolyl, benzimidazolyl, ~~imidazolylphenyl, phenylimidazolyl, pthalamido,~~ napthyl, ~~benzophenone, anilinyl, anisolyl,~~ quinolinyl, ~~quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl,~~ 9H-fluoren-1-yl, ~~piperidin-1-yl, piperidin-1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl,~~ or furanyl, ~~furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-1-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, 1,4'-bipiperidin-1'-yl, and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl~~.

93. (Currently amended) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein A_1 in formula (II) is selected from the group consisting of ~~substituted or unsubstituted phenyl,~~ chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl,

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl, trifluorophenyl, (trifluoromethyl)thiophenyl, alkoxybiphenyl, hydroxyphenyl, hydroxyalkylphenyl, 4-amino(imino)methylphenyl and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl.

94. (Previously presented) The method of claim 93, wherein A_1 in formula (II) is 4-bromophenyl.

95. (Previously presented) The method of claim 93, wherein A_1 in formula (II) is trifluoromethylchlorophenyl.

96. (Currently amended) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein A_2 in formula (II) is selected from the group consisting of ~~substituted or~~ unsubstituted ~~phenyl,~~ pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyrazinyl, triazolyl, thiophenyl, furanyl, quinolinyl, purinyl, ~~naphthyl,~~ benzothiazolyl, benzopyridyl and benzoimidazolyl.

97. (Currently amended) The method of claim 96, wherein A_2 in formula (II) is unsubstituted pyridyl.

98. (Currently amended) The method of claim 96, wherein A_2 in formula (II) is





LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

99. (Currently amended) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein R_1 is taken together with R_2 in formula (II) to form a substituted ~~or unsubstituted C_{3-8} heterocycloalkyl or~~ C_{3-14} heteroaryl group, wherein the C_{3-14} heteroaryl group contains only carbon and nitrogen atoms as ring atoms.

100. (Currently amended) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein R_1 is taken together with R_2 in formula (II) to form a group selected from substituted ~~or unsubstituted phenyl,~~ pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyrazinyl, triazolyl, thiophenyl, furanyl, quinolinyl, purinyl, ~~naphthyl,~~ benzothiazolyl, benzopyridyl and benzoimidazolyl.

101. (Currently amended) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein R_1 is taken together with R_2 in formula (II) to form a substituted ~~or unsubstituted~~ imidazolyl group.

102. (Previously presented) The method of claim 100, wherein the imidazolyl group is substituted with a halo C_{1-6} alkyl group.

103. (Previously presented) The method of claim 100, wherein the imidazolyl group is substituted with a trifluoromethyl group.

104-107. (Canceled)

108. (Previously presented) The method of claim 75, wherein the cancer is melanoma.

109. (Previously presented) The method of claim 75, wherein the cancer is a carcinoma of the lungs, pancreas, thyroid, bladder or colon.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

110. (Previously presented) The method of claim 75, wherein the cancer is myeloid leukemia.

111. (Previously presented) The method of claim 75, wherein the cancer is villous colon adenoma.

112. (Previously presented) The method of claim 82 wherein the hematological cancer disorder is chronic myelogenous leukemia.

113. (New) The method of claim 75, wherein A_1 in formula (II) is selected from the group consisting of phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclylcarbonylphenyl, heterocyclylphenyl, heterocyclylalkylphenyl, chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl, 2,3-dihydroindenyl, tetralinyl, trifluorophenyl, (trifluoromethyl)thiophenyl, alkoxybiphenyl, indolyl, 2,3-dihydroindolyl, 1-acetyl-2,3-dihydroindolyl, hydroxyphenyl, hydroxyalkylphenyl, 4-amino(imino)methylphenyl, imidazolylphenyl, phenylimidazolyl, pthalamido, benzophenone, anilinyl, anisolyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanylphenyl, pyrrolidin-4-ylpyridinyl, and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl.

114. (New) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein the variables in formula (II) are as follows:

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

A_1 is a substituted carbocyclic aryl group;

A_2 is unsubstituted pyridyl;

R_1 is taken together with R_2 to form a substituted C_{3-14} heteroaryl group, wherein the C_{3-14} heteroaryl group contains only carbon and nitrogen atoms as ring atoms; and

R_4 is C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.